Does elevated stool inflammation with normal calprotectin and no white blood cells suggest mucosal immune activation?

In evaluating gastrointestinal symptoms, analyzing specific biomarker patterns helps pinpoint the nature of mucosal inflammation.

Clinical evidence

• Ruling out neutrophilic pathology: Fecal calprotectin, a calcium-binding protein found mainly in neutrophil cytoplasm, and fecal leukocytes serve as sensitive markers for neutrophil-driven mucosal inflammation. A normal fecal calprotectin level (<50 µg/g) coupled with the absence of stool white blood cells effectively rules out active, prominent neutrophil-dominant inflammation, such as classic active inflammatory bowel disease (IBD).

Mechanistic explanations

• Non-neutrophilic immune activation: The absence of active neutrophils does not preclude other forms of mucosal immune activation. Pathologies like microscopic colitis (including collagenous and lymphocytic colitis) and eosinophilic gastroenteritis are driven by lymphocytes, mast cells, or eosinophils rather than neutrophils.
• Alternative biomarkers: In these non-neutrophilic processes, eosinophil-specific markers—such as eosinophil cationic protein (ECP) or eosinophil protein X (EPX)—can be highly elevated. These proteins serve as reliable indicators of active mucosal immune activation and eosinophil degranulation even while neutrophil-specific markers remain entirely within normal limits.

Bottom line

• A stool profile demonstrating elevated inflammatory markers alongside normal calprotectin (<50 µg/g) and absent white blood cells is highly suggestive of non-neutrophilic mucosal immune activation, effectively ruling out classic neutrophil-dominant inflammation.